Dafna Capital Management LLC Neurocrine Biosciences Inc Transaction History

Dafna Capital Management LLC

$368 Million
Q3 2025

A detailed history of Dafna Capital Management LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Dafna Capital Management LLC holds 70,615 shares of NBIX stock, worth $10.2 Million. This represents 2.69% of its overall portfolio holdings.

Number of Shares

70,615

Previous 70,615 -0.0%

Holding current value

$10.2 Million

Previous $8.88 Million 11.68%

% of portfolio

2.69%

Previous 2.58%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$87.54 - $128.18 $87,540 - $128,180	-1,000 Reduced 1.4%	70,615 $8.88 Million
Q4 2024 Feb 14, 2025	BUY	$111.62 - $139.44 $223,240 - $278,880	2,000 Added 2.87%	71,615 $9.78 Million
Q3 2024 Nov 14, 2024	SELL	$114.58 - $153.15 $229,160 - $306,300	-2,000 Reduced 2.79%	69,615 $8.01 Million
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $130,400 - $143,740	-1,000 Reduced 1.38%	71,615 $9.88 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $106,070 - $132,760	-1,000 Reduced 1.36%	72,615 $9.57 Million

Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $94,020 - $117,100	-1,000 Reduced 1.34%	73,615 $8.28 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $140,600 - $183,791	1,494 Added 2.04%	74,615 $7.55 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $750,668 - $893,740	-7,034 Reduced 8.78%	73,121 $8.73 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $230,075 - $269,525	-2,500 Reduced 3.02%	80,155 $8.51 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $75,790 - $100,070	-1,000 Reduced 1.2%	82,655 $8.06 Million
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $79,650 - $106,220	-1,000 Reduced 1.18%	83,655 $7.13 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $947,980 - $1.09 Million	11,000 Added 14.93%	84,655 $8.12 Million
Q1 2021 May 17, 2021	SELL	$87.57 - $119.4 $1.62 Million - $2.22 Million	-18,553 Reduced 20.12%	73,655 $7.16 Million
Q4 2020 Feb 16, 2021	BUY	$86.91 - $108.33 $173,820 - $216,660	2,000 Added 2.22%	92,208 $8.84 Million
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $1.63 Million - $2.3 Million	17,000 Added 23.22%	90,208 $8.67 Million
Q2 2020 Aug 14, 2020	SELL	$85.09 - $130.36 $595,630 - $912,520	-7,000 Reduced 8.73%	73,208 $8.93 Million
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $1.44 Million - $2.18 Million	19,200 Added 31.47%	80,208 $6.94 Million
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $303,800 - $414,995	-3,500 Reduced 5.43%	61,008 $6.56 Million
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $8,382 - $10,150	-100 Reduced 0.15%	64,508 $5.81 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $693,504 - $876,192	9,600 Added 17.45%	64,608 $5.46 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $956,479 - $1.74 Million	14,000 Added 34.14%	55,008 $3.93 Million
Q3 2018 Nov 14, 2018	SELL	$98.88 - $125.85 $444,960 - $566,325	-4,500 Reduced 9.89%	41,008 $5.04 Million
Q2 2018 Aug 13, 2018	SELL	$75.3 - $105.99 $677,700 - $953,910	-9,000 Reduced 16.51%	45,508 $4.47 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $2.61 Million - $3.34 Million	54,508	54,508 $3.34 Million

Others Institutions Holding NBIX

# of Institutions

741

Shares Held

102M

Call Options Held

230K

Put Options Held

477K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dafna Capital Management LLC with notifications on news.

Account

Dafna Capital Management LLC Neurocrine Biosciences Inc Transaction History